Identification

Name
Nisoldipine
Accession Number
DB00401  (APRD00635)
Type
Small Molecule
Groups
Approved
Description

Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.

Structure
Thumb
Synonyms
  • isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
  • Nisoldipin
  • Nisoldipina
  • Nisoldipine
  • Nisoldipino
  • Nisoldipinum
External IDs
Bay K 5552
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SularTablet, film coated, extended release25.5 mg/1OralPhysicians Total Care, Inc.2009-02-24Not applicableUs
SularTablet, film coated, extended release17 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release17 mg/1OralShionogi1995-02-02Not applicableUs
SularTablet, film coated, extended release8.5 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release8.5 mg/1OralShionogi1995-02-02Not applicableUs
SularTablet, film coated, extended release34 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release34 mg/1OralShionogi1995-02-02Not applicableUs59630 0503 10 nlmimage10 4f1627b1
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NisoldipineTablet, film coated, extended release40 mg/1OralPhysicians Total Care, Inc.2008-08-29Not applicableUs
NisoldipineTablet, film coated, extended release20 mg/1OralMylan Pharmaceuticals2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release25.5 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs00378 2097 01 nlmimage10 de3bef7f
NisoldipineTablet, film coated, extended release17 mg/1OralPrasco, Laboratories2012-02-27Not applicableUs
NisoldipineTablet, film coated, extended release40 mg/1OralMylan Pharmaceuticals2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release34 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs00378 2099 01 nlmimage10 243c1250
NisoldipineTablet, film coated, extended release8.5 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs00677 1979 01 nlmimage10 9b084de2
NisoldipineTablet, film coated, extended release8.5 mg/1OralPrasco, Laboratories2012-02-27Not applicableUs
International/Other Brands
Baymycard (Bayer) / Baymycard RR (Bayer) / Bo Ping (Rui Yang Pharm) / Di Yi Xin (Tasly) / Ji Ni Le Er (Jiankang Pharmaceutical) / Ninobarucin (Choseido Pharmaceutical) / Nisomynard (Yoshindo) / Riohard (Taiyo Pharmaceutical) / Ruidi (Nanjing Sanrui Pharmaceutical Co.) / Sular / Syscor (Bayer)
Categories
UNII
4I8HAB65SZ
CAS number
63675-72-9
Weight
Average: 388.4144
Monoisotopic: 388.16343651
Chemical Formula
C20H24N2O6
InChI Key
VKQFCGNPDRICFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
IUPAC Name
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C

Pharmacology

Indication

For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Associated Conditions
Pharmacodynamics

Nisoldipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
Absorption

Relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4.

Route of elimination

Although 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine.

Half life

7-12 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nisoldipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nisoldipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Nisoldipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nisoldipine.Experimental
AcebutololNisoldipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nisoldipine.Approved, Vet Approved
Acetyl sulfisoxazoleThe metabolism of Nisoldipine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nisoldipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nisoldipine.Approved, Investigational
AliskirenNisoldipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololNisoldipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanNisoldipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNisoldipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmiodaroneThe metabolism of Nisoldipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Nisoldipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Nisoldipine.Approved
AmobarbitalThe metabolism of Nisoldipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Nisoldipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nisoldipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Nisoldipine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nisoldipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Nisoldipine.Approved, Investigational
ApalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nisoldipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Nisoldipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nisoldipine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Nisoldipine.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Nisoldipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Nisoldipine.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Nisoldipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Nisoldipine.Approved
AtomoxetineThe metabolism of Nisoldipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nisoldipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Nisoldipine.Experimental
BarbexacloneThe metabolism of Nisoldipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nisoldipine can be increased when combined with Barbital.Illicit
BarnidipineNisoldipine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilNisoldipine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideNisoldipine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nisoldipine.Approved, Investigational
BepridilNisoldipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Nisoldipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Nisoldipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Nisoldipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nisoldipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nisoldipine.Approved, Investigational
BimatoprostNisoldipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololNisoldipine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Nisoldipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BoceprevirThe metabolism of Nisoldipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Nisoldipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.Approved
BQ-123Nisoldipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Nisoldipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.Approved, Investigational
BretyliumNisoldipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Nisoldipine.Approved, Investigational
BrigatinibThe serum concentration of Nisoldipine can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Nisoldipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nisoldipine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nisoldipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Nisoldipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Nisoldipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nisoldipine.Approved, Investigational
BupranololNisoldipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Nisoldipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nisoldipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nisoldipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Nisoldipine.Experimental
CafedrineNisoldipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Canagliflozin.Approved
CandesartanNisoldipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilNisoldipine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Nisoldipine.Withdrawn
CandoxatrilNisoldipine may increase the hypotensive activities of Candoxatril.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Nisoldipine.Experimental
CaptoprilNisoldipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Nisoldipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nisoldipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Nisoldipine.Withdrawn
CarteololNisoldipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolNisoldipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Nisoldipine.Approved
CeliprololNisoldipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Nisoldipine.Approved
ChlorothiazideNisoldipine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Nisoldipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nisoldipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nisoldipine.Approved
CicletanineNisoldipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Nisoldipine.Approved, Investigational
CilazaprilNisoldipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nisoldipine.Approved, Investigational
CimetidineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClarithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.Approved
ClarithromycinThe metabolism of Nisoldipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nisoldipine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nisoldipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nisoldipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Nisoldipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.Approved
CloranololNisoldipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Nisoldipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nisoldipine.Approved
CobicistatThe serum concentration of Nisoldipine can be increased when it is combined with Cobicistat.Approved
CobicistatThe metabolism of Nisoldipine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nisoldipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nisoldipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nisoldipine.Investigational
CrizotinibThe metabolism of Nisoldipine can be decreased when combined with Crizotinib.Approved
CryptenamineNisoldipine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe serum concentration of Nisoldipine can be increased when it is combined with Curcumin.Approved, Investigational
CurcuminThe metabolism of Nisoldipine can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideNisoldipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideNisoldipine may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine.Approved
DabrafenibThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nisoldipine.Approved
DarunavirThe serum concentration of Nisoldipine can be increased when it is combined with Darunavir.Approved
DarunavirThe metabolism of Nisoldipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Nisoldipine.Approved, Investigational
DeferasiroxThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilNisoldipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Nisoldipine can be decreased when combined with Delavirdine.Approved
DeserpidineNisoldipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nisoldipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Nisoldipine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Nisoldipine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Nisoldipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineNisoldipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nisoldipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nisoldipine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nisoldipine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nisoldipine.Approved, Investigational
DiltiazemThe metabolism of Nisoldipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole.Approved
DorzolamideNisoldipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Nisoldipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Nisoldipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine.Approved, Investigational
DoxycyclineThe metabolism of Nisoldipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nisoldipine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Nisoldipine.Approved, Vet Approved
DuloxetineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nisoldipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.Approved
EfavirenzThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nisoldipine.Approved
EfonidipineNisoldipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.Approved
EnalaprilNisoldipine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatNisoldipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nisoldipine.Experimental
EnzalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.Approved
EpanololNisoldipine may increase the hypotensive activities of Epanolol.Experimental
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Nisoldipine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eplerenone.Approved
EpoprostenolNisoldipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanNisoldipine may increase the hypotensive activities of Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nisoldipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nisoldipine.Approved
ErythromycinThe metabolism of Nisoldipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Nisoldipine.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nisoldipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.Approved
FelodipineNisoldipine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamNisoldipine may increase the hypotensive activities of Fenoldopam.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nisoldipine.Experimental
Ferulic acidNisoldipine may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nisoldipine.Approved, Investigational
FluconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Nisoldipine.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Nisoldipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nisoldipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Nisoldipine.Approved
FluvoxamineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nisoldipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilNisoldipine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FosphenytoinThe metabolism of Nisoldipine can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nisoldipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Nisoldipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Nisoldipine.Approved, Investigational, Vet Approved
GuanabenzNisoldipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nisoldipine.Approved
GuanazodineNisoldipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNisoldipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
GuanoclorNisoldipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNisoldipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNisoldipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Nisoldipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Nisoldipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nisoldipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nisoldipine.Experimental
HexamethoniumNisoldipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Nisoldipine.Approved, Investigational
HexobarbitalThe metabolism of Nisoldipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nisoldipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Nisoldipine.Approved
HydrochlorothiazideNisoldipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideNisoldipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nisoldipine.Approved
IdelalisibThe serum concentration of Nisoldipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Nisoldipine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nisoldipine.Approved, Investigational
ImatinibThe metabolism of Nisoldipine can be decreased when combined with Imatinib.Approved
ImidaprilNisoldipine may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nisoldipine.Approved
IndapamideNisoldipine may increase the hypotensive activities of Indapamide.Approved
IndenololNisoldipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nisoldipine can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Nisoldipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Nisoldipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nisoldipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nisoldipine.Withdrawn
IrbesartanNisoldipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nisoldipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nisoldipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nisoldipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nisoldipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Nisoldipine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nisoldipine can be increased when it is combined with Ivacaftor.Approved
KetanserinKetanserin may increase the hypotensive activities of Nisoldipine.Investigational
KetoconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Nisoldipine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolNisoldipine may increase the hypotensive activities of Labetalol.Approved
LacidipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostNisoldipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nisoldipine.Approved
LercanidipineNisoldipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nisoldipine.Approved, Investigational
LevodopaNisoldipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nisoldipine.Approved, Investigational
LinsidomineNisoldipine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nisoldipine.Approved, Investigational
LisinoprilNisoldipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Nisoldipine.Approved, Investigational
LofexidineNisoldipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.Approved
LopinavirThe metabolism of Nisoldipine can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Nisoldipine can be increased when it is combined with Lorpiprazole.Approved
LosartanNisoldipine may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nisoldipine.Approved, Investigational
LuliconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nisoldipine can be decreased when it is combined with Lumacaftor.Approved
LumacaftorThe metabolism of Nisoldipine can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nisoldipine.Illicit, Investigational, Withdrawn
MacitentanNisoldipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineNisoldipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nisoldipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Nisoldipine.Approved, Nutraceutical, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Nisoldipine.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nisoldipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Nisoldipine can be increased when combined with Methohexital.Approved
MethoserpidineNisoldipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nisoldipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.Approved
MethyldopaNisoldipine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nisoldipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nisoldipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Nisoldipine can be increased when combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nisoldipine.Approved
MetipranololNisoldipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneNisoldipine may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MetyrosineNisoldipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Nisoldipine.Experimental
MibefradilNisoldipine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Nisoldipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Nisoldipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nisoldipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Nisoldipine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Nisoldipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Nisoldipine.Investigational
MitotaneThe serum concentration of Nisoldipine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MoexiprilNisoldipine may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Nisoldipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nisoldipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MuzolimineNisoldipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Nisoldipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nisoldipine.Approved, Investigational
NadololNisoldipine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Nisoldipine.Approved
NaftopidilNisoldipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nisoldipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Nisoldipine.Approved
NebivololNisoldipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NefazodoneThe metabolism of Nisoldipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Nisoldipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nisoldipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Nisoldipine can be decreased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Nisoldipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nisoldipine.Withdrawn
NicardipineNisoldipine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Nisoldipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Nisoldipine.Experimental
NiguldipineNisoldipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Nisoldipine.Investigational
NilotinibThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNisoldipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nisoldipine.Approved
NitrendipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nisoldipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNisoldipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Nisoldipine.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Nisoldipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Nisoldipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Nisoldipine.Approved, Vet Approved
ObinutuzumabNisoldipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Nisoldipine.Approved, Investigational
OlaparibThe metabolism of Nisoldipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
OmapatrilatNisoldipine may increase the hypotensive activities of Omapatrilat.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nisoldipine.Experimental
OsimertinibThe serum concentration of Nisoldipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nisoldipine.Approved
OxprenololNisoldipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nisoldipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nisoldipine.Investigational
PalbociclibThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Nisoldipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Nisoldipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.Approved
PenbutololNisoldipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nisoldipine.Approved, Investigational
PentobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentobarbitalThe metabolism of Nisoldipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumNisoldipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nisoldipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nisoldipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilNisoldipine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nisoldipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhenobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenobarbitalThe metabolism of Nisoldipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineNisoldipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhentolamineNisoldipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhenytoinThe metabolism of Nisoldipine can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Nisoldipine.Approved
PindololNisoldipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nisoldipine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Nisoldipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nisoldipine.Approved
PitolisantThe serum concentration of Nisoldipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Nisoldipine.Approved
Platelet Activating FactorNisoldipine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideNisoldipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe metabolism of Nisoldipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nisoldipine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.Approved
PrazosinPrazosin may increase the hypotensive activities of Nisoldipine.Approved
PrimidoneThe serum concentration of Nisoldipine can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Nisoldipine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Nisoldipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nisoldipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nisoldipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Nisoldipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nisoldipine.Approved, Investigational, Vet Approved
PropranololNisoldipine may increase the hypotensive activities of Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nisoldipine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Nisoldipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.Approved
QuinaprilNisoldipine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nisoldipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nisoldipine.Approved
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nisoldipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Nisoldipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Nisoldipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nisoldipine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nisoldipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nisoldipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Nisoldipine.Approved
RescinnamineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
RibociclibThe serum concentration of Nisoldipine can be increased when it is combined with Ribociclib.Approved, Investigational
RifabutinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifabutinThe metabolism of Nisoldipine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifampicin.Approved
RifampicinThe metabolism of Nisoldipine can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Nisoldipine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifapentineThe metabolism of Nisoldipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nisoldipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nisoldipine.Approved
RiociguatNisoldipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNisoldipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabNisoldipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nisoldipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nisoldipine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nisoldipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nisoldipine.Approved
RucaparibThe metabolism of Nisoldipine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nisoldipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nisoldipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Nisoldipine.Approved, Investigational, Vet Approved
SaprisartanNisoldipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Nisoldipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Nisoldipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
SelexipagNisoldipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nisoldipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nisoldipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.Approved
SiltuximabThe serum concentration of Nisoldipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nisoldipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nisoldipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Nisoldipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Nisoldipine.Approved, Investigational
SitaxentanNisoldipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.Approved
SpiraprilNisoldipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nisoldipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nisoldipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nisoldipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nisoldipine.Approved
SulfisoxazoleThe metabolism of Nisoldipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
TalinololNisoldipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nisoldipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Nisoldipine.Approved, Investigational
TelaprevirThe serum concentration of Nisoldipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelaprevirThe metabolism of Nisoldipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Telithromycin.Approved
TelithromycinThe metabolism of Nisoldipine can be decreased when combined with Telithromycin.Approved
TelmisartanNisoldipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilNisoldipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Nisoldipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Nisoldipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nisoldipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nisoldipine.Experimental
TerlipressinNisoldipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineNisoldipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nisoldipine.Approved, Investigational, Withdrawn
TheodrenalineNisoldipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Nisoldipine.Approved
ThiamylalThe metabolism of Nisoldipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nisoldipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nisoldipine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nisoldipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Nisoldipine.Approved
TiboloneNisoldipine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Nisoldipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNisoldipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Nisoldipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nisoldipine.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nisoldipine.Approved, Investigational
TocilizumabThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineNisoldipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nisoldipine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Nisoldipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Nisoldipine.Approved, Investigational, Vet Approved
TolonidineNisoldipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nisoldipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nisoldipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nisoldipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Nisoldipine.Approved
TrandolaprilNisoldipine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Nisoldipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Nisoldipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nisoldipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.Approved
TrichlormethiazideNisoldipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nisoldipine.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Nisoldipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Nisoldipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nisoldipine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
UnoprostoneNisoldipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Nisoldipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nisoldipine.Approved
VemurafenibThe serum concentration of Nisoldipine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Nisoldipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Nisoldipine can be decreased when combined with Verapamil.Approved
VincamineNisoldipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Nisoldipine.Approved, Investigational
VinpocetineNisoldipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Voriconazole.Approved, Investigational
VoriconazoleThe metabolism of Nisoldipine can be decreased when combined with Voriconazole.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nisoldipine.Experimental
XipamideNisoldipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineNisoldipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Nisoldipine.Approved, Investigational, Vet Approved
ZiprasidoneThe metabolism of Nisoldipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilNisoldipine may increase the hypotensive activities of Zofenopril.Experimental
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nisoldipine.Approved, Investigational
Food Interactions
  • Do not take with grapefruit juice as this has been shown to interfere with nisoldipine metabolism, resulting in a mean increase in Cmax of about 3-fold (up to about 7-fold) and AUC of almost 2-fold (up to 5-fold).

References

Synthesis Reference

Massimo Ferrari, Marcello Ghezzi, Manuel Alberelli, Alberto Ambrosini, "Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine)." U.S. Patent US20050240022, issued October 27, 2005.

US20050240022
General References
  1. Mielcarek J, Grobelny P, Szamburska O: The effect of beta-carotene on the photostability of nisoldipine. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):167-71. [PubMed:15834448]
  2. Missan S, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF: Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70. Epub 2003 Oct 6. [PubMed:14530219]
  3. Hamilton SF, Houle LM, Thadani U: Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec;1(5):279-88. [PubMed:11720635]
External Links
Human Metabolome Database
HMDB0014545
KEGG Drug
D00618
KEGG Compound
C07699
PubChem Compound
4499
PubChem Substance
46504546
ChemSpider
4343
BindingDB
50011689
ChEBI
76917
ChEMBL
CHEMBL1726
Therapeutic Targets Database
DAP000595
PharmGKB
PA450634
IUPHAR
2524
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nisoldipine
ATC Codes
C08CA07 — Nisoldipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
4CompletedTreatmentDiabetic Nephropathies1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Shionogi pharma inc
Packagers
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bayer Healthcare
  • Bryant Ranch Prepack
  • Heartland Repack Services LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Physicians Total Care Inc.
  • Quality Care
  • Remedy Repack
  • Sciele Pharma Inc.
  • Shionogi Pharma Inc.
  • Skyepharma Production Sas
  • United Research Laboratories Inc.
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral17 mg/1
Tablet, film coated, extended releaseOral25.5 mg/1
Tablet, film coated, extended releaseOral34 mg/1
Tablet, film coated, extended releaseOral8.5 mg/1
Prices
Unit descriptionCostUnit
Sular 25.5 mg 24 Hour tablet6.84USD tablet
Sular 34 mg 24 Hour tablet6.84USD tablet
Sular 17 mg 24 Hour tablet6.48USD tablet
Sular 34 mg tablet5.64USD tablet
Sular 17 mg tablet5.17USD tablet
Nisoldipine er 30 mg tablet5.07USD tablet
Nisoldipine er 40 mg tablet5.07USD tablet
Sular 10 mg tablet5.04USD tablet
Sular 8.5 mg 24 Hour tablet5.04USD tablet
Nisoldipine er 20 mg tablet4.65USD tablet
Sular 25.5 mg tablet4.35USD tablet
Sular 8.5 mg tablet4.13USD tablet
Sular 20 mg tablet3.37USD tablet
Sular 30 mg 24 Hour tablet3.23USD tablet
Sular 40 mg 24 Hour tablet3.23USD tablet
Sular 30 mg tablet3.1USD tablet
Sular 40 mg tablet2.61USD tablet
Sular 10 mg 24 Hour tablet2.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5626874No1994-11-302014-11-30Us
US5422123No1995-06-062012-06-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.26MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00577 mg/mLALOGPS
logP3.63ALOGPS
logP3.06ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)5.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.91 m3·mol-1ChemAxon
Polarizability39.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9357
Blood Brain Barrier-0.947
Caco-2 permeable+0.6928
P-glycoprotein substrateSubstrate0.5548
P-glycoprotein inhibitor IInhibitor0.8824
P-glycoprotein inhibitor IIInhibitor0.9239
Renal organic cation transporterNon-inhibitor0.8925
CYP450 2C9 substrateNon-substrate0.7874
CYP450 2D6 substrateNon-substrate0.8929
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateInhibitor0.8782
CYP450 2C9 inhibitorInhibitor0.7826
CYP450 2D6 inhibitorNon-inhibitor0.9141
CYP450 2C19 inhibitorInhibitor0.7804
CYP450 3A4 inhibitorInhibitor0.8414
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8982
Ames testNon AMES toxic0.778
CarcinogenicityNon-carcinogens0.5782
BiodegradationNot ready biodegradable0.9335
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.9175
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, diester, methyl ester, dihydropyridine (CHEBI:76917)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hu H, Marban E: Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol Pharmacol. 1998 May;53(5):902-7. [PubMed:9584217]
  3. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638]
  4. Wei X, Pan S, Lang W, Kim H, Schneider T, Perez-Reyes E, Birnbaumer L: Molecular determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity and allosteric regulation of dihydropyridine binding. J Biol Chem. 1995 Nov 10;270(45):27106-11. [PubMed:7592963]
  5. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:18